Nicolas Madranges

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)

Hervé Bonnefoi, Thomas Grellety, Olivier Trédan et al. · Annals of Oncology · 2016 · 281 citations · Full text

Medicine, Oncology, Pharmacology +17

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9

Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis

Elvire Pons‐Tostivint, Youlia Kirova, Amélie Lusque et al. · Annals of Surgical Oncology · 2018 · 56 citations

Medicine, Biostatistics, Oncology +16

Radiation therapy to the primary tumor for de novo metastatic breast cancer and overall survival in a retrospective multicenter cohort analysis

Elvire Pons‐Tostivint, Youlia Kirova, Amélie Lusque et al. · Radiotherapy and Oncology · 2020 · 37 citations

Medicine, Oncology, Radiation Oncology +17

Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer

Nathalie Quénel-Tueux, Marc Debled, Justine Rudewicz et al. · British Journal of Cancer · 2015 · 28 citations · Full text

Medicine, Molecular Medicine, Oncology +17